Immunogenicity and Tolerability of a Heptavalent Pneumococcal Conjugate Vaccine Administered at 3, 5 and 12 Months of Age
- 1 February 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 24 (2) , 108-114
- https://doi.org/10.1097/01.inf.0000151022.92222.be
Abstract
The recommended vaccination schedule for the pneumococcal conjugate vaccine (PCV) includes 4 immunizations, according to the national programs in the United States and some European countries. Other countries use a national schedule for routine vaccinations in early childhood that includes only 3 doses. The goals were to assess the immunogenicity and tolerability of PCV with a vaccination schedule that included 3 doses during the first 1 year of life (a 2+1 dose schedule) and to determine the immune responses to concomitantly administered Haemophilus influenzae type b (Hib) vaccine. A total of 101 healthy Swedish infants were enrolled in an open, nonrandomized, multicenter study. PCV was administered concomitantly with (at separate sites) a diphtheria-tetanus toxoids-acellular pertussis vaccine, inactivated polio vaccine and Hib conjugate vaccine combination at 3, 5 and 12 months of age. IgG antibody concentrations for the 7 serotypes included in the PCV and the Hib capsular polysaccharide in serum samples taken at 3, 6, 12 and 13 months were determined with enzyme immunoassays. Local and systemic reactions were monitored for 3 days after each immunization, and serious adverse reactions were monitored for the whole study period. Two doses of PCV induced satisfactory antibody responses, with the exception of serotypes 6B and 23F. The third dose evoked strong responses for all serotypes, which suggests good immunologic priming with the primary series of 2 doses. The mean anti-Hib antibody concentrations were similar to those noted in earlier studies among Swedish children. The PCV was well tolerated. The pneumococcal antibody concentrations at 13 months were comparable with those noted previously with the 4-dose schedule. The results suggest that the implementation of a 2+1 dose schedule for PCV should be considered.Keywords
This publication has 36 references indexed in Scilit:
- Protective Efficacy of a Second Pneumococcal Conjugate Vaccine against Pneumococcal Acute Otitis Media in Infants and Children: Randomized, Controlled Trial of a 7-Valent Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine in 1666 ChildrenClinical Infectious Diseases, 2003
- Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate VaccineNew England Journal of Medicine, 2003
- Pneumococcal conjugate vaccines: proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and ChemotherapyVaccine, 2003
- Capsular Types and Antibiotic Susceptibility of Invasive Streptococcus pneumoniae Among Children in SwedenScandinavian Journal of Infectious Diseases, 2003
- Development and Evaluation of Pneumococcal Conjugate Vaccines: Clinical Trials and Control TestsCritical Reviews in Microbiology, 2002
- Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccineThe Pediatric Infectious Disease Journal, 2001
- Pneumococcal conjugate vaccines in Europe, Berlin, Germany, 23-25 August 2000. Report of a European advisory board meeting.Vaccine, 2001
- Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis MediaNew England Journal of Medicine, 2001
- Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in childrenThe Pediatric Infectious Disease Journal, 2000
- Nasopharyngeal Colonization in Southern Israel with Antibiotic-Resistant Pneumococci during the First 2 Years of Life: Relation to Serotypes Likely to Be Included in Pneumococcal Conjugate VaccinesThe Journal of Infectious Diseases, 1996